(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 151.82% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Durect's revenue in 2025 is $2,031,000.On average, 2 Wall Street analysts forecast DRRX's revenue for 2025 to be $35,698,278, with the lowest DRRX revenue forecast at $24,833,585, and the highest DRRX revenue forecast at $46,562,972. On average, 2 Wall Street analysts forecast DRRX's revenue for 2026 to be $246,628,539, with the lowest DRRX revenue forecast at $46,562,972, and the highest DRRX revenue forecast at $446,694,107.
In 2027, DRRX is forecast to generate $1,226,468,669 in revenue, with the lowest revenue forecast at $1,226,468,669 and the highest revenue forecast at $1,226,468,669.